An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.
Padovani L, Baret A, Ciccolini J, Taieb D, Bardia F, Teissonnier L, Muracciole X, Barlesi F, Barbolosi D
Fabrice Barlesi
PU-PH Publications
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso PM, Burris HA, Gordon MS, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott DF, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey KM, Mahrus S, Morley R, Pirzkall A, Davis SL